Intravase® Approval Opens Vascular Market for Cytori

  Intravase® Approval Opens Vascular Market for Cytori

Cytori Receives CE Mark for Specialized Cell Therapy Reagent for Intravascular

Business Wire

SAN DIEGO -- February 25, 2013

Cytori Therapeutics (NASDAQ: CYTX) has received a CE Mark in Europe for
Intravase^®, a reagent intended to be used with Cytori’s Celution^® System for
preparing safe and optimized adipose-derived stem and regenerative cells
(ADRCs) for intravascular delivery into the same patient.

“This approval expands our market access for our cell therapy platform to
include intravascular applications,” said Marc Hedrick, President of Cytori
Therapeutics. “As a result, this is expected to contribute to revenue growth
in 2013 and beyond. We will target select centers to build patient data, which
we believe can be used to further expand these claims and increase the
adoption of our technology. Furthermore, CE Mark approval of Intravase will
allow independent European investigators to conduct their own vascular

Intravase is a sterile, GMP-grade secondary reagent used with the Celution
System to prepare the Celution cell output for safe intravascular delivery.
Intravase is currently being used in both our U.S. ATHENA trial in patients
with refractory heart failure due to chronic myocardial ischemia and the
European ADVANCE trial for acute heart attack patients.

About Adipose Tissue and ADRCs

Adipose tissue is the richest source of stem and regenerative cells in the
body. This mixed population of cells, collectively referred to as ADRCs, is
accessible at the point-of-care through the Celution System for use in the
same patient, creating new treatment opportunities for currently unmet medical
needs. ADRCs collectively contribute to the healing process via cell-to-cell
signaling, supporting improved blood flow and regulation of the inflammatory

About Cytori

Cytori Therapeutics is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
other medical conditions. Our scientific data suggest ADRCs improve blood
flow, moderate the inflammatory response and keep tissue at risk of dying
alive. As a result, we believe these cells can be applied across multiple
“ischemic” conditions. These therapies are made available to the physician and
patient at the point-of-care by Cytori’s proprietary technologies and
products, including the Celution System product family.

Cautionary Statement Regarding Forward-Looking Statements

This communication includes forward-looking statements regarding events,
trends and business prospects, which may affect our future operating results
and financial position. Such statements, including, but not limited to, those
regarding our expectation that the approval will have a significant
contribution to our future revenue growth, expand our ability to obtain
European regulatory claims, and increase investigative use of the Celution
System in Europe and market adoption of our technology, are subject to risks
and uncertainties that could cause our actual results and financial position
to differ materially. Some of these risks and uncertainties include the
challenges inherent in convincing physicians and patients to adopt the new
technology, successfully expanding our European claims as well as our history
of operating losses, regulatory uncertainties, dependence on third party
performance, and other risks and uncertainties described under the "Risk
Factors" section in Cytori's Securities and Exchange Commission Filings on
Form 10-K and Form 10-Q. Cytori assumes no responsibility to update or revise
any forward-looking statements contained in this press release to reflect
events, trends or circumstances after the date of this press release.


Cytori Therapeutics
Tom Baker
Megan McCormick
Press spacebar to pause and continue. Press esc to stop.